Jpmorgan Chase & CO Sab Biotherapeutics, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.62 - $1.0 $14 - $24	24 Added 2.59%	951 $0
Q3 2023 Nov 14, 2023	BUY	$0.47 - $0.9 $21 - $41	46 Added 5.22%	927 $0
Q4 2022 Feb 13, 2023	SELL	$0.54 - $9.8 $941 - $17,091	-1,744 Reduced 66.44%	881 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.13 - $12.4 $106 - $10,130	817 Added 45.19%	2,625 $2,000
Q2 2022 Aug 11, 2022	SELL	$1.11 - $3.46 $3,543 - $11,044	-3,192 Reduced 63.84%	1,808 $3,000
Q1 2022 May 11, 2022	BUY	$1.78 - $8.5 $2,079 - $9,928	1,168 Added 30.48%	5,000 $19,000
Q4 2021 Feb 10, 2022	BUY	$7.3 - $11.24 $27,973 - $43,071	3,832 New	3,832 $30,000

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $111M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.